Chemoinformaics analysis of (-)-Norargemonine
| Molecular Weight | 341.407 | nRot | 3 |
| Heavy Atom Molecular Weight | 318.223 | nRig | 1 |
| Exact Molecular Weight | 341.163 | nRing | 4 |
| Solubility: LogS | -2.523 | nHRing | 2 |
| Solubility: LogP | 2.83 | No. of Aliphatic Rings | 2 |
| Acid Count | 0 | No. of Aromatic Rings | 2 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 2 |
| No. of Heavy Atom | 25 | No. of Aromatic Carbocycles | 2 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 23 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 12 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 12 |
| nHA | 5 | APOL | 53.0442 |
| nHD | 1 | BPOL | 29.9918 |
| QED | 0.436 |
| Synth | 1.528 |
| Natural Product Likeliness | 0.482 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Rejected |
| Pgp-inh | 0.039 |
| Pgp-sub | 0.013 |
| HIA | 0.003 |
| CACO-2 | -4.364 |
| MDCK | 0.0000277 |
| BBB | 0.997 |
| PPB | 0.689962 |
| VDSS | 0.726 |
| FU | 0.401353 |
| CYP1A2-inh | 0.956 |
| CYP1A2-sub | 0.791 |
| CYP2c19-inh | 0.559 |
| CYP2c19-sub | 0.806 |
| CYP2c9-inh | 0.254 |
| CYP2c9-sub | 0.839 |
| CYP2d6-inh | 0.016 |
| CYP2d6-sub | 0.183 |
| CYP3a4-inh | 0.051 |
| CYP3a4-sub | 0.185 |
| CL | 9.255 |
| T12 | 0.834 |
| hERG | 0.037 |
| Ames | 0.01 |
| ROA | 0.061 |
| SkinSen | 0.765 |
| Carcinogencity | 0.271 |
| EI | 0.978 |
| Respiratory | 0.282 |
| NR-Aromatase | 0.014 |
| Antiviral | Yes |
| Prediction | 0.657562 |